Ampio Pharmaceuticals (AMPE) Competitors $0.0027 -0.16 (-98.36%) As of 10/3/2025 01:31 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AMPE vs. NAVB, EVLO, GNCAQ, GNCA, STAB, CMRA, SYRS, EFTR, HSTO, and PXMDShould you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Comera Life Sciences (CMRA), Syros Pharmaceuticals (SYRS), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry. Ampio Pharmaceuticals vs. Its Competitors Navidea Biopharmaceuticals Evelo Biosciences Genocea Biosciences Genocea Biosciences Statera Biopharma Comera Life Sciences Syros Pharmaceuticals eFFECTOR Therapeutics Histogen PaxMedica Ampio Pharmaceuticals (NYSE:AMPE) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings. Does the media prefer AMPE or NAVB? In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Ampio Pharmaceuticals Neutral Navidea Biopharmaceuticals Neutral Do insiders & institutionals believe in AMPE or NAVB? 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, AMPE or NAVB? Ampio Pharmaceuticals has a beta of 5.13, meaning that its share price is 413% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Which has stronger valuation & earnings, AMPE or NAVB? Ampio Pharmaceuticals has higher earnings, but lower revenue than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00Navidea Biopharmaceuticals$8.13K0.00-$15.18MN/AN/A Is AMPE or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Ampio PharmaceuticalsN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A SummaryAmpio Pharmaceuticals beats Navidea Biopharmaceuticals on 3 of the 5 factors compared between the two stocks. Get Ampio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPE vs. The Competition Export to ExcelMetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3K$1.03B$6.10B$22.14BDividend YieldN/A4.84%5.64%3.55%P/E Ratio0.001.2885.7030.04Price / SalesN/A145.50527.9869.64Price / CashN/A17.6426.3018.34Price / Book0.007.2312.894.66Net Income-$8.63M-$7.70M$3.30B$1.01B7 Day PerformanceN/A17.42%4.68%1.33%1 Month PerformanceN/A21.50%7.99%3.33%1 Year PerformanceN/A53.35%75.79%14.24% Ampio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPEAmpio PharmaceuticalsN/A$0.00-98.4%N/A+22.7%$3KN/A0.0020NAVBNavidea BiopharmaceuticalsN/A$0.00-50.0%N/AN/A$10K$8.13K0.0010EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Gap DownGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070STABStatera BiopharmaN/A$0.00flatN/AN/A$5KN/A0.0020CMRAComera Life SciencesN/AN/AN/AN/A$3K$1.00M0.002News CoverageSYRSSyros Pharmaceuticals3.8404 of 5 stars$0.00flat$1.00+999,900.0%-99.7%$3K$386K0.00120Gap UpEFTReFFECTOR Therapeutics0.0653 of 5 stars$0.00flatN/A-99.2%$1KN/A0.0010High Trading VolumeHSTOHistogenN/A$0.00flatN/AN/A$1K$19K0.0020Gap UpPXMDPaxMedicaN/AN/AN/AN/A$1KN/A0.002 Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Statera Biopharma Competitors Comera Life Sciences Competitors Syros Pharmaceuticals Competitors eFFECTOR Therapeutics Competitors Histogen Competitors PaxMedica Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AMPE) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
